<DOC>
	<DOCNO>NCT01804920</DOCNO>
	<brief_summary>Presently generally effective treatment tardive dyskinesia ( TD ) available . D-serine naturally occur amino acid act in-vivo positive allosteric modulator glycine site associate glutamatergic NMDA receptor . Previous study suggest D-serine may improve motor symptom , include dyskinesia , cause treatment presently use antipsychotic drug . The hypothesis investigation present study D-serine adjuvant treatment may improve TD schizophrenia patient diagnose disorder .</brief_summary>
	<brief_title>D-Serine Treatment For Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>1. age 1870 ; 2. diagnosis schizophrenia/schizoaffective disorder accord DSMIV criterion ; diagnosis make basis SCID interview information medical record , previous treat psychiatrist , family informant ; 3. history â‰¥3 month antipsychotic drug treatment present stable dose antipsychotic treatment last 4 week ; 4. fulfillment SchoolerKane TD research criterion first evaluation perform 212 week prior study entrance subsequent evaluation perform prior allocation experimental treatment . 1. meeting criterion DSMIV Axis I diagnose ; 2. presence neurological disorder history significant head injury ; 3. substance abuse alcoholism entire lifetime ; 4. judge clinically suicidal homicidal risk ; 5. female patient pregnant lactating ; female patient pregnant lactating , sexually active , must use medically accept mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>